Cargando…

Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer

OBJECTIVES: To investigate whether changes to the apparent diffusion coefficient (ADC) of primary tumour in the early period after starting chemotherapy can predict progression-free survival (PFS) or overall survival (OS) in patients with unresectable pancreatic adenocarcinoma. METHODS: Subjects com...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiofuku, Hideyuki, Tanaka, Toshihiro, Marugami, Nagaaki, Sho, Masayuki, Akahori, Takahiro, Nakajima, Yoshiyuki, Kichikawa, Kimihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863905/
https://www.ncbi.nlm.nih.gov/pubmed/26385808
http://dx.doi.org/10.1007/s00330-015-3999-2
_version_ 1782431559382466560
author Nishiofuku, Hideyuki
Tanaka, Toshihiro
Marugami, Nagaaki
Sho, Masayuki
Akahori, Takahiro
Nakajima, Yoshiyuki
Kichikawa, Kimihiko
author_facet Nishiofuku, Hideyuki
Tanaka, Toshihiro
Marugami, Nagaaki
Sho, Masayuki
Akahori, Takahiro
Nakajima, Yoshiyuki
Kichikawa, Kimihiko
author_sort Nishiofuku, Hideyuki
collection PubMed
description OBJECTIVES: To investigate whether changes to the apparent diffusion coefficient (ADC) of primary tumour in the early period after starting chemotherapy can predict progression-free survival (PFS) or overall survival (OS) in patients with unresectable pancreatic adenocarcinoma. METHODS: Subjects comprised 43 patients with histologically confirmed unresectable pancreatic cancer treated with first-line chemotherapy. Minimum ADC values in primary tumour were measured using the selected area ADC (sADC), which excluded cystic and necrotic areas and vessels, and the whole tumour ADC (wADC), which included whole tumour components. Relative changes in ADC were calculated from baseline to 4 weeks after initiation of chemotherapy. Relationships between ADC and both PFS and OS were modelled by Cox proportional hazards regression. RESULTS: Median PFS and OS were 6.1 and 11.0 months, respectively. In multivariate analysis, sADC change was the strongest predictor of PFS (hazard ratio (HR), 4.5; 95 % confidence interval (CI), 1.7–11.9; p = 0.002). Multivariate Cox regression analysis for OS revealed sADC change and CRP as independent predictive markers, with sADC change as the strongest predictive biomarker (HR, 6.7; 95 % CI, 2.7–16.6; p = 0.001). CONCLUSION: Relative changes in sADC could provide a useful imaging biomarker to predict PFS and OS with chemotherapy for unresectable pancreatic adenocarcinoma. KEY POINTS: • Relative change in ADC value can predict survival in unresectable pancreatic cancer. • ADC change could determine a chemosensitivity of pancreatic cancer. • ADC values should be measured by excluding cystic, necrotic areas and vessels.
format Online
Article
Text
id pubmed-4863905
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-48639052016-05-25 Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer Nishiofuku, Hideyuki Tanaka, Toshihiro Marugami, Nagaaki Sho, Masayuki Akahori, Takahiro Nakajima, Yoshiyuki Kichikawa, Kimihiko Eur Radiol Oncology OBJECTIVES: To investigate whether changes to the apparent diffusion coefficient (ADC) of primary tumour in the early period after starting chemotherapy can predict progression-free survival (PFS) or overall survival (OS) in patients with unresectable pancreatic adenocarcinoma. METHODS: Subjects comprised 43 patients with histologically confirmed unresectable pancreatic cancer treated with first-line chemotherapy. Minimum ADC values in primary tumour were measured using the selected area ADC (sADC), which excluded cystic and necrotic areas and vessels, and the whole tumour ADC (wADC), which included whole tumour components. Relative changes in ADC were calculated from baseline to 4 weeks after initiation of chemotherapy. Relationships between ADC and both PFS and OS were modelled by Cox proportional hazards regression. RESULTS: Median PFS and OS were 6.1 and 11.0 months, respectively. In multivariate analysis, sADC change was the strongest predictor of PFS (hazard ratio (HR), 4.5; 95 % confidence interval (CI), 1.7–11.9; p = 0.002). Multivariate Cox regression analysis for OS revealed sADC change and CRP as independent predictive markers, with sADC change as the strongest predictive biomarker (HR, 6.7; 95 % CI, 2.7–16.6; p = 0.001). CONCLUSION: Relative changes in sADC could provide a useful imaging biomarker to predict PFS and OS with chemotherapy for unresectable pancreatic adenocarcinoma. KEY POINTS: • Relative change in ADC value can predict survival in unresectable pancreatic cancer. • ADC change could determine a chemosensitivity of pancreatic cancer. • ADC values should be measured by excluding cystic, necrotic areas and vessels. Springer Berlin Heidelberg 2015-09-19 2016 /pmc/articles/PMC4863905/ /pubmed/26385808 http://dx.doi.org/10.1007/s00330-015-3999-2 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Oncology
Nishiofuku, Hideyuki
Tanaka, Toshihiro
Marugami, Nagaaki
Sho, Masayuki
Akahori, Takahiro
Nakajima, Yoshiyuki
Kichikawa, Kimihiko
Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer
title Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer
title_full Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer
title_fullStr Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer
title_full_unstemmed Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer
title_short Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer
title_sort increased tumour adc value during chemotherapy predicts improved survival in unresectable pancreatic cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863905/
https://www.ncbi.nlm.nih.gov/pubmed/26385808
http://dx.doi.org/10.1007/s00330-015-3999-2
work_keys_str_mv AT nishiofukuhideyuki increasedtumouradcvalueduringchemotherapypredictsimprovedsurvivalinunresectablepancreaticcancer
AT tanakatoshihiro increasedtumouradcvalueduringchemotherapypredictsimprovedsurvivalinunresectablepancreaticcancer
AT marugaminagaaki increasedtumouradcvalueduringchemotherapypredictsimprovedsurvivalinunresectablepancreaticcancer
AT shomasayuki increasedtumouradcvalueduringchemotherapypredictsimprovedsurvivalinunresectablepancreaticcancer
AT akahoritakahiro increasedtumouradcvalueduringchemotherapypredictsimprovedsurvivalinunresectablepancreaticcancer
AT nakajimayoshiyuki increasedtumouradcvalueduringchemotherapypredictsimprovedsurvivalinunresectablepancreaticcancer
AT kichikawakimihiko increasedtumouradcvalueduringchemotherapypredictsimprovedsurvivalinunresectablepancreaticcancer